XML 97 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
STOCK-BASED COMPENSATION PLANS
12 Months Ended
Dec. 31, 2019
STOCK-BASED COMPENSATION PLANS [Abstract]  
STOCK-BASED COMPENSATION PLANS
NOTE L:  STOCK-BASED COMPENSATION PLANS

The Company has a long-term incentive program for directors, officers and employees.  Under this program, the Company initially authorized four million shares of Company common stock for the grant of incentive stock options, nonqualified stock options, restricted stock awards, and retroactive stock appreciation rights.  The long-term incentive program was amended effective May 25, 2011, May 14, 2014 and May 17, 2017 to authorize an additional 900,000 shares, 1,000,000 shares and 1,000,000 shares of Company common stock, respectively, for the grant of incentive stock options, nonqualified stock options, restricted stock awards, and retroactive stock appreciation rights.  As of December 31, 2019, the Company has authorization to grant up to approximately 1.2 million additional shares of Company common stock for these instruments.  The nonqualified (offset) stock options in its Director’s Stock Balance Plan vest and become exercisable immediately and expire one year after the date the director retires or two years in the event of death.  The remaining options have a ten-year term, and vest and become exercisable on a grant-by-grant basis, ranging from immediate vesting to ratably over a five-year period.

Activity in this long-term incentive program is as follows:


Stock Options
 
Outstanding
 
Weighted-
average Exercise
Price of Shares
Outstanding at December 31, 2017
 
1,708,296
 
$
34.57
Granted
 
213,504
 
 
55.92
Exercised
 
(268,004)
 
 
27.94
Forfeited
 
(9,435)
 
 
45.54
Outstanding at December 31, 2018
 
1,644,361
 
 
38.36
Granted
 
199,110
 
 
59.41
Exercised
 
(331,315)
 
 
30.42
Forfeited
 
(9,162)
 
 
51.29
Outstanding at December 31, 2019
 
1,502,994
 
 
42.82
Exercisable at December 31, 2019
 
929,120
 
$
36.73

The following table summarizes the information about stock options outstanding under the Company’s stock option plan at December 31, 2019:


 
Options outstanding
 
Options exercisable
 
Range of Exercise
Price
 
Shares
 
Weighted-
average
Exercise
Price
 
Weighted-
average
Remaining
Life (years)
 
Shares
 
Weighted-
average
Exercise
Price
 
$0.00 – $28.00
 
 
96,324
 
$
79.25
 
 
3.36
 
 
96,324
 
$
24.26
 
$28.001 – $29.00
 
 
97,492
 
 
28.78
 
 
2.22
 
 
97,492
 
 
28.78
 
$29.001 – $30.00
 
 
141,501
 
 
29.79
 
 
3.21
 
 
141,501
 
 
29.79
 
$30.001 – $40.00
 
 
594,156
 
 
37.09
 
 
5.38
 
 
453,418
 
 
37.05
 
$40.001 – $60.00
 
 
573,521
 
 
57.47
 
 
8.24
 
 
140,385
 
 
56.76
 
TOTAL
 
 
1,502,994
 
$
42.82
 
 
5.93
 
 
929,120
 
$
36.73
 

The weighted-average remaining contractual term of outstanding and exercisable stock options at December 31, 2019 is 5.93 years and 4.77 years, respectively.  The aggregate intrinsic value of outstanding and exercisable stock options at December 31, 2019 is $42.3 million and $31.8 million, respectively.

The Company recognized stock-based compensation expense related to non-qualified stock options of $2.2 million, $2.6 million and $2.2 million for the years ended December 31, 2019, 2018 and 2017, respectively.  A related income tax benefit was recognized of $0.5 million, $0.6 million and $0.8 million for the 2019, 2018 and 2017 years, respectively.  Compensation expense related to restricted stock vesting recognized in the income statement for 2019, 2018 and 2017 was approximately $2.8 million, $3.2 million and $2.7 million, respectively.

Management estimated the fair value of options granted using the Black-Scholes option-pricing model.  This model was originally developed to estimate the fair value of exchange-traded equity options, which (unlike employee stock options) have no vesting period or transferability restrictions.  As a result, the Black-Scholes model is not necessarily a precise indicator of the value of an option, but it is commonly used for this purpose. The Black-Scholes model requires several assumptions, which management developed based on historical trends and current market observations.


 
2019
   
2018
   
2017
 
Weighted-average Fair Value of Options Granted
 
$
14.16
   
$
13.44
   
$
12.78
 
Assumptions:
                       
Weighted-average expected life (in years)
   
6.50
     
6.50
     
6.50
 
Future dividend yield
   
2.73
%
   
2.91
%
   
3.19
%
Share price volatility
   
29.31
%
   
29.44
%
   
29.71
%
Weighted-average risk-free interest rate
   
2.44
%
   
2.82
%
   
2.31
%

Unrecognized stock-based compensation expense related to non-vested stock options totaled $5.1 million at December 31, 2019.  The weighted-average period over which this unrecognized expense would be recognized is 3.3 years.  The total fair value of stock options vested during 2019, 2018, and 2017 were $2.4 million, $2.3 million and $2.2 million, respectively.

During the 12 months ended December 31, 2019 and 2018, proceeds from stock option exercises totaled $11.3 million and $9.4 million, respectively, and the related tax benefits from exercise were approximately $2.3 million and $1.6 million, respectively.   During the twelve months ended December 31, 2019 and 2018, approximately 0.3 million shares were issued in connection with stock option exercises each year.  The total intrinsic value of options exercised during 2019, 2018 and 2017 were $11.6 million, $8.4 million and $7.6 million, respectively.

A summary of the status of the Company’s unvested restricted stock awards as of December 31, 2019, and changes during the twelve months ended December 31, 2019 and 2018, is presented below:


Restricted
Shares
 
Weighted-average
grant date fair value
Unvested at December 31, 2017
230,873
 
$
34.06
Awards
50,133
 
 
55.92
Forfeitures
(3,429)
 
 
34.95
Vestings
(56,514)
 
 
39.40
Unvested at December 31, 2018
221,063
 
 
37.72
Awards
108,556
 
 
42.53
Forfeitures
(2,365)
 
 
52.47
Vestings
(130,466)
 
 
29.71
Unvested at December 31, 2019
196,788
 
$
45.58

Unrecognized stock-based compensation expense related to unvested restricted stock totaled $6.6 million at December 31, 2019, which will be recognized as expense over the next five years.  The weighted-average period over which this unrecognized expense would be recognized is 4.7 years.  The total fair value of restricted stock vested during 2019, 2018, and 2017 were $3.8 million, $2.3 million and $2.2 million, respectively.